Hello, everyone, and how are you this cold morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made is this far, which is a likely sign of surviving another few days. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Meanwhile, we have a modified schedule today, thanks to a presentation we are scheduled to make. Wish us luck. Hope you conquer the world and, as always, do keep in touch …

Roche (RHHBY) is halting two late-stage clinical trials of its crenezumab drug for early Alzheimer’s disease after an interim analysis indicated it was unlikely to hit its primary goal, Reuters says. The announcement by Roche, which has been working on the product with AC Immune, marks the latest high-profile failure of an Alzheimer’s drug following the 2016 flop of an experimental medicine from Eli Lilly (LLY). The failures have undermined conviction in the beta amyloid hypothesis, in which a protein forms plaques in the brain and likely plays a pivotal role in the disorder.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy